Significant progress in ICI development has instigated a paradigm shift in patients with lung cancer, especially those with locally advanced NSCLC without EGFR/ALK alterations, for whom ICIs have been approved as second-line therapy after numerous trials [9,110,111,112]. Here, EGFR is linked to non-small cell lung carcinoma.